Insider Selling: Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Insider Sells 2,816 Shares of Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) insider Caroline Baumal sold 2,816 shares of the stock in a transaction on Monday, January 6th. The stock was sold at an average price of $33.81, for a total transaction of $95,208.96. Following the sale, the insider now directly owns 55,560 shares of the company’s stock, valued at $1,878,483.60. This represents a 4.82 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Apellis Pharmaceuticals Stock Performance

Shares of APLS stock traded down $1.63 during trading on Wednesday, reaching $33.00. 1,620,566 shares of the company’s stock were exchanged, compared to its average volume of 2,311,633. Apellis Pharmaceuticals, Inc. has a twelve month low of $24.34 and a twelve month high of $73.80. The firm’s fifty day moving average price is $31.66 and its 200-day moving average price is $33.83. The company has a quick ratio of 3.73, a current ratio of 4.36 and a debt-to-equity ratio of 1.91. The stock has a market capitalization of $4.10 billion, a PE ratio of -16.26 and a beta of 0.94.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.14). The company had revenue of $196.83 million during the quarter, compared to the consensus estimate of $200.00 million. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. Apellis Pharmaceuticals’s revenue for the quarter was up 78.3% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.17) earnings per share. As a group, sell-side analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.72 EPS for the current year.

Institutional Investors Weigh In On Apellis Pharmaceuticals

Several hedge funds have recently bought and sold shares of the stock. Rhumbline Advisers lifted its holdings in Apellis Pharmaceuticals by 2.2% during the 2nd quarter. Rhumbline Advisers now owns 123,565 shares of the company’s stock worth $4,740,000 after purchasing an additional 2,644 shares during the last quarter. Arizona State Retirement System lifted its holdings in shares of Apellis Pharmaceuticals by 12.7% during the second quarter. Arizona State Retirement System now owns 22,013 shares of the company’s stock worth $844,000 after buying an additional 2,473 shares in the last quarter. Savant Capital LLC acquired a new stake in shares of Apellis Pharmaceuticals during the second quarter worth $522,000. State of New Jersey Common Pension Fund D boosted its position in shares of Apellis Pharmaceuticals by 6.6% in the second quarter. State of New Jersey Common Pension Fund D now owns 45,241 shares of the company’s stock valued at $1,735,000 after acquiring an additional 2,820 shares during the period. Finally, Oppenheimer Asset Management Inc. grew its stake in shares of Apellis Pharmaceuticals by 46.7% in the second quarter. Oppenheimer Asset Management Inc. now owns 12,754 shares of the company’s stock valued at $489,000 after acquiring an additional 4,060 shares in the last quarter. 96.29% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Bank of America lowered their target price on Apellis Pharmaceuticals from $61.00 to $47.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. Scotiabank dropped their target price on Apellis Pharmaceuticals from $35.00 to $30.00 and set a “sector perform” rating on the stock in a research report on Wednesday, November 6th. Oppenheimer reduced their price target on Apellis Pharmaceuticals from $65.00 to $40.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. Needham & Company LLC lowered their price objective on shares of Apellis Pharmaceuticals from $85.00 to $60.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Finally, HC Wainwright reduced their target price on shares of Apellis Pharmaceuticals from $83.00 to $57.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. Eight analysts have rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, Apellis Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $49.94.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).